On March 3, 2022 MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will participate in the following investor conferences in March 2022 (Press release, MacroGenics, MAR 3, 2022, View Source [SID1234609451]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen 42nd Annual Health Care Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate on the Gastrointestinal/Genitourinary Oncology Panel, Tuesday, March 8, 2022, at 10:30 am ET. Management will also participate in one-on-one meetings.
Barclays Global Healthcare Conference. MacroGenics’ management is scheduled to participate in a fireside chat and provide a corporate overview on Tuesday, March 15, 2022, at 3:50 pm ET. Management will also participate in one-on-one meetings.
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.

On March 3, 2022 Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer therapeutics, reported that Bill Newell, Chief Executive Officer, will participate in the Ovarian Cancer Panel at the Cowen 42nd Annual Healthcare Conference on Wednesday, March 9, 2022, at 12:50 p.m. ET / 9:50 a.m. PT (Press release, Sutro Biopharma, MAR 3, 2022, View Source [SID1234609467]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. A replay of the webcast will be available for approximately 30 days following the event.

On March 3, 2022 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported the publication of an article in BioTechniques describing a novel technology that provides for very low levels of expression of one gene module, while maintaining high levels of expression of other gene modules expressed from the same promotor1 (Press release, Autolus, MAR 3, 2022, View Source [SID1234609482]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This technical paper describes a method of achieving very low levels of transgene expression in multi-cistronic mammalian expression systems. This is achieved via the insertion of a stop codon and translational readthrough motif (TRM) between the transgenes of an mRNA encoding a multi-cistronic cassette. The TRM helps to suppress the stop codon, facilitating continued translation of the downstream transgene at reduced levels compared with the upstream transgene. This system addresses a fundamental challenge in cell therapy when highly potent receptors, cytokines or toxins are expressed, which, at normal levels of expression, would be unsafe for patients.

"Throughout the history of gene-therapy the primary focus was on engineering mammalian expression cassettes driving high levels of transgene expression," said James Sillibourne, director of synthetic genomics at Autolus. "However, with a very potent or toxic transgene, you need a very low level of expression. Up until now, an easy way of achieving this was not available. Building on mechanisms known from bacteria and viruses, we have developed a reliable way of tightly controlling low levels of transgene expression."

IL-12 is a potent anti-tumor cytokine. However, the majority of clinical studies involving treatment of patients with IL-12 have been associated with severe systemic side effects and significant toxicities for patients.

"Our approach to solid tumors combines multiple gene modules in CAR T cells to drive the desired set of properties we believe are essential to maximize anti-tumor activity without increasing toxicity. Selectively adjusting expression levels became an important technology to establish therapeutic windows," added Martin Pule, chief scientific officer and founder of Autolus. "In this paper we successfully applied this technology for highly restricted IL-12 release which increases CAR T anti-tumor activity in an immunocompetent mouse model without inducing systemic toxicity."

1. Sillibourne JE, Agliardi G, Righi M et al. A compact and simple method of achieving differential transgene expression by exploiting translational readthrough. BioTechniques doi: 10.2144/btn-2021-0079 (2022) (Epub ahead of print). The full publication in BioTechniques can be viewed here.

On March 3, 2022 Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, reported that it will present at the 34th Annual ROTH Conference being held both virtually and in-person in Dana Point, California on March 13-15, 2022 (Press release, Evogene, MAR 3, 2022, View Source [SID1234609498]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference will feature on-demand online and live presentations from companies across a variety of sectors, one-on-one and small group meetings, industry panels, and fireside chats. Past conferences have drawn thousands of attendees, including institutional investors, analysts, family offices and high net-worth investors.

Evogene’s CEO, Ofer Haviv will participate in a live, in-person fireside chat on Tuesday, March 15 at 12pm PT. Furthermore, Mr. Haviv, will participate in one-on-one meetings with institutional analysts and investors throughout the days of the conference.

Investors that wish to meet in-person with Mr. Haviv, are welcome to coordinate the meeting via their Roth representatives. Alternatively, investors may contact Evogene’s investor relations team which will coordinate either a face-to-face meeting with the CEO at the conference or alternatively a virtual meeting in the weeks following.

On March 2, 2022 Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated exposure-response analyses from the Phase 1b platinum-resistant ovarian cancer and Phase 1b clear cell renal cancer trials at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting taking place between April 8-13, 2022 in New Orleans, Louisiana (Press release, Aravive, MAR 2, 2022, View Source [SID1234609352]). The abstract presentation at AACR (Free AACR Whitepaper) will be presented virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Title: Exposure-Response Analysis of Batiraxcept and Application to Recommended Phase 2 Dose in Platinum-Resistant Ovarian and Clear Cell Renal Cancers
Abstract Number: 7867
Presentation Type: Remote Poster Presentation
Date: April 8, 2022